Spero Therapeutics Inc (NASDAQ:SPRO) – Stock analysts at Cantor Fitzgerald dropped their FY2018 earnings per share estimates for shares of Spero Therapeutics in a research report issued to clients and investors on Tuesday, April 3rd. Cantor Fitzgerald analyst L. Chen now anticipates that the company will earn ($3.70) per share for the year, down from their prior estimate of ($3.69). Cantor Fitzgerald currently has a “Buy” rating and a $27.00 target price on the stock.
Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Monday, April 2nd. The company reported ($1.59) earnings per share for the quarter, topping the consensus estimate of ($1.77) by $0.18. The firm had revenue of $0.99 million for the quarter, compared to analyst estimates of $0.40 million.
Spero Therapeutics stock opened at $14.26 on Friday. Spero Therapeutics has a fifty-two week low of $9.66 and a fifty-two week high of $15.40.
Several institutional investors have recently added to or reduced their stakes in SPRO. TIAA CREF Investment Management LLC acquired a new position in shares of Spero Therapeutics during the 4th quarter worth about $103,000. California State Teachers Retirement System acquired a new position in Spero Therapeutics in the 4th quarter valued at about $112,000. Dean Capital Investments Management LLC acquired a new position in Spero Therapeutics in the 4th quarter valued at about $118,000. Deutsche Bank AG acquired a new position in Spero Therapeutics in the 4th quarter valued at about $155,000. Finally, California Public Employees Retirement System acquired a new position in Spero Therapeutics in the 4th quarter valued at about $294,000. Institutional investors own 46.28% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3334469/fy2018-eps-estimates-for-spero-therapeutics-inc-reduced-by-analyst-spro.html.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.